09

  • Brain malformations linked to protein misfolding

    Mutations in a complex that helps proteins fold correctly are tied to developmental disorders that include seizures and intellectual disability, Stanford Medicine-led research has found.

  • AI tool reads biopsy images

    Researchers used artificial intelligence to predict the activity of thousands of genes in tumors based on routinely collected images of tumor biopsies. It could guide treatment without costly genomic tests.

  • Stanford CME online program addition

    Stanford Medicine launches a pilot program collaboration to expand its CME courses to a broader audience worldwide, setting a new standard for online medical education.

  • CAR-T cells fight brain, spinal tumors

    CAR-T cells show promise against pediatric diffuse midline gliomas, brain and spinal cord tumors that are among the deadliest cancers, a Stanford Medicine trial found.

  • Antibody composition shapes flu severity

    Why do some people develop severe flu symptoms? A Stanford Medicine study points the finger at an unsung portion of the antibodies our immune systems generate to fend off invading pathogens.

  • ecDNA catapults into spotlight

    Tiny circles called ecDNA are critical in cancer development and drug resistance. An international Stanford Medicine-led team publishes landmark studies detailing new findings and potential therapies.

  • Digital health forum stresses equity

    Artificial intelligence and digital technology experts convened to discuss the benefits, challenges and potential of a digitally driven future in biomedical research and health care.

  • Colon cancer screening options

    Blood tests for colorectal cancer are an option for patients who would otherwise not be screened, but they are not as effective as colonoscopies or stool tests, a Stanford Medicine-led study found.

  • $70 million NIH grant

    The goal of the Clinical and Translational Science Award is to convert new treatments into care more rapidly.

  • Driving cancer cells to self-destruct

    Stanford researchers hope new technique will flip lymphoma protein’s normal action — from preventing cell death to triggering it.